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Abstract
Background: Subgroup analyses from randomized trials suggested favorable results for 
the direct oral anticoagulants in fragile patients with venous thromboembolism (VTE). 
The frequency and natural history of fragile patients with VTE have not been studied yet.
Objectives: To compare the clinical characteristics, treatment and outcomes during 
the first 3 months of anticoagulation in fragile vs non- fragile patients with VTE.
Methods: Retrospective study using consecutive patients enrolled in the RIETE 
(Registro Informatizado Enfermedad TromboEmbolica) registry. Fragile patients were 
defined as those having age ≥75 years, creatinine clearance (CrCl) levels ≤50 mL/min, 
and/or body weight ≤50 kg.
Results: From January 2013 to October 2016, 15 079 patients were recruited. Of 
these, 6260 (42%) were fragile: 37% were aged ≥75 years, 20% had CrCl levels 
≤50 mL/min, and 3.6% weighed ≤50 kg. During the first 3 months of anticoagulant 
therapy, fragile patients had a lower risk of VTE recurrences (0.78% vs 1.4%; adjusted 
odds ratio [OR]: 0.52; 95% confidence intervals [CI]: 0.37- 0.74) and a higher risk of 
major bleeding (2.6% vs 1.4%; adjusted OR: 1.41; 95% CI: 1.10- 1.80), gastrointestinal 
[Article updated on September 15, 2017, after 
first online publication on September 4, 2017: 
The table within Figure 1 has been updated so 
that the columns reflect number of days, not 
months.]
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1  | INTRODUCTION
In recent years, a number of direct oral anticoagulants (DOACs) have 
been developed for the treatment of venous thromboembolism (VTE). 
Their use has been associated with a lower rate of major bleeding com-
pared with standard therapy.1–5 Hence, apixaban, rivaroxaban, dabiga-
tran, and edoxaban have been approved for the treatment of patients 
with deep vein thrombosis (DVT) or pulmonary embolism (PE).6 
Subgroup analyses from these randomized clinical trials have delivered 
further promising results, particularly for the so- called fragile patients, 
defined as those having creatinine clearance (CrCl) levels ≤50 mL/min, 
age ≥75 years, or body weight ≤50 kg.3–5,7 Hence, there are reasons to 
suggest that fragile patients with VTE could be considered ideal can-
didates for long- term therapy with DOACs.4,5,7,8 However, the propor-
tion of fragile patients in real life, and their outcome during the course 
of anticoagulant therapy have not been thoroughly studied yet.
RIETE (Registro Informatizado Enfermedad TromboEmbólica) is 
a multicenter, ongoing, international (Spain, Belgium, Brazil, Canada, 
Czech Republic, Ecuador, France, Israel, Italy, Latvia, Republic of 
Macedonia, Switzerland, and the United States enroll patients) registry 
of consecutive patients with symptomatic, objectively confirmed, acute 
VTE (ClinicalTrials.gov identifier: NCT02832245).9–13 Since its inception 
in 2001, the aim of RIETE is to record data including the clinical charac-
teristics, treatment patterns, and outcomes in patients diagnosed with 
VTE. Using the RIETE database, the current study compared the clinical 
characteristics, treatment, and outcomes during the first 3 months of 
anticoagulation in fragile vs non- fragile patients with acute VTE.
2  | PATIENTS AND METHODS
2.1 | Inclusion criteria
Consecutive patients presenting with symptomatic, acute DVT or PE 
confirmed by objective tests (compression ultrasonography or contrast 
venography for DVT; helical CT- scan, ventilation- perfusion lung scin-
tigraphy or angiography for PE) were enrolled in RIETE. Patients were 
excluded if they were currently participating in a therapeutic clinical 
trial with a blinded therapy. All patients (or their legal power of attor-
ney) provided written or oral consent for participation in the registry, 
in accordance with local ethics committee requirements.
Physicians participating in the RIETE registry made all efforts to enroll 
consecutive patients. Data were recorded onto a computer- based case- 
report form at each participating hospital and submitted to a centralized 
coordinating center through a secure website. To ensure the validity of 
the information entered into the database, one of the specially trained 
monitors visited each participating hospital and compared information 
in 25- 50 randomly chosen patient records with the information entered 
into the RIETE database. For data quality assessment, monitors assessed 
4100 random records from all participating hospitals, which included 
1 230 000 measurements. These data showed a 95% overall agreement 
between the registered information and patient records. RIETE also 
used electronic data monitoring to detect inconsistencies or errors and 
attempted to resolve discrepancies by contacting the local coordinators.
2.2 | Study design
We conducted a cohort study that used consecutive patients enrolled 
in the RIETE registry. For this study, only patients recruited from 
January 2013 (the year when the first DOAC was approved for use in 
patients with VTE) were considered. Our aim was to compare the clin-
ical characteristics, treatment, and outcomes in fragile vs non- fragile 
patients. The major outcome was the rate of VTE recurrences or major 
bleeding occurring during the first 3 months of anticoagulant therapy.
2.3 | Definitions
Fragile patients were defined as those having CrCl levels ≤50 mL/min, 
age ≥75 years, or body weight ≤50 kg.3 Immobilized patients were 
bleeding (0.86% vs 0.35%; adjusted OR: 1.84; 95% CI: 1.16- 2.92), haematoma (0.51% 
vs 0.07%; adjusted OR: 5.05; 95% CI: 2.05- 12.4), all- cause death (9.2% vs 3.5%; 
 adjusted OR: 2.02; 95% CI: 1.75- 2.33), or fatal PE (0.85% vs 0.35%; adjusted OR: 1.77; 
95% CI: 1.10- 2.85) than the non- fragile.
Conclusions: In real life, 42% of VTE patients were fragile. During anticoagulation, they 
had fewer VTE recurrences and more major bleeding events than the non- fragile.
K E Y W O R D S
anticoagulants, hemorrhage, mortality, recurrences, venous thromboembolism
Essentials
• Recent randomized trials suggested fewer bleeding events in fragile patients with VTE receiving DOACs.
• The frequency, clinical characteristics and outcome of these patients have not been reported in real life.
• Fragile patients with VTE had a higher risk for major bleeding or death and a lower risk for recurrences than non-fragile.
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defined as non- surgical patients who had been immobilized (ie, total 
bed rest with bathroom privileges) for ≥4 days in the 2- month period 
prior to VTE.12 Surgical patients were defined as those who under-
went a surgical intervention in the 2 months prior to VTE.11 Active 
cancer was defined as newly diagnosed cancer, metastatic cancer, or 
cancer that was being treated (ie, surgery, chemotherapy, radiother-
apy, support therapy).10 Recent bleeding was defined as any major 
bleeding episode <30 days prior to VTE.14 Bleeding events were clas-
sified as “major” if they were overt and required a transfusion of two 
units or more of blood, or were retroperitoneal, spinal, or intracra-
nial, or when they were fatal. Fatal bleeding was defined as any death 
occurring within 10 days of a major bleeding episode, in the absence 
of an alternative cause of death.14 Fatal PE, in the absence of autopsy, 
was defined as any death appearing within 10 days after symptomatic 
PE diagnosis, in the absence of any alternative cause of death.12 Initial 
therapy was defined as any therapy administered during the first 
week in case of low- molecular- weight heparin (LMWH), unfraction-
ated heparin, fondaparinux, or apixaban, and during the first 3 weeks 
in case of rivaroxaban. Long- term therapy was defined as any therapy 
administered after the end of initial therapy.
2.4 | Treatment and follow- up
Patients were managed according to each participating hospital’s clini-
cal practice, and there were no standardized or recommended duration 
of therapy or follow- up. All patients had to be followed- up for at least 
3 months in the outpatient clinic or physician’s office. During each 
visit, any signs or symptoms suggesting VTE recurrences or bleeding 
complications were noted. Each episode of clinically suspected recur-
rent VTE was investigated by repeat compression ultrasonography, 
lung scanning, helical- CT scan, or pulmonary angiography, as appro-
priate. Most outcomes were classified as reported by the clinical cent-
ers. However, if staff at the coordinating center were uncertain how 
to classify a reported outcome, that event was reviewed by a central 
adjudicating committee (less than 10% of events).
2.5 | Statistical analysis
Clinical characteristics, risk factors, and initial VTE presentation were 
analyzed using descriptive statistics for continuous variables and fre-
quency counts and percentages for categorical variables. Categorical 
TABLE  1 Clinical characteristics in 15 079 fragile and non- fragile patients with acute venous thromboembolism
Non- fragile Fragile Age ≥ 75 y Weight ≤ 50 kg CrCl ≤ 50 mL/min
Patients, N 8819 6260 5514 537 3059
Clinical characteristics
 Age (y ± SD) 55 ± 14 80 ± 10‡ 82 ± 5.0 71 ± 2.0 81 ± 10
 Gender (male) 5058 (57%) 2407 (38%)‡ 2104 (38%) 73 (14%) 1030 (34%)
 Body weight (kg ± SD) 81 ± 17 71 ± 14‡ 72 ± 14 47 ± 4. 67 ± 13
Risk factors for VTE
 Immobilization ≥4 d 1342 (15%) 1648 (26%)‡ 1488 (27%) 165 (31%) 894 (29%)
 Surgery 1097 (12%) 502 (8.0%)‡ 406 (7.4%) 48 (8.9%) 228 (7.5%)
 Cancer 1894 (21%) 1495 (24%)‡ 1235 (22%) 164 (31%) 723 (24%)
 Estrogen use 813 (9.2%) 222 (3.5%)‡ 160 (2.9%) 53 (9.9%) 92 (3.0%)
 Pregnancy/puerperium 172 (2.0%) 7 (0.11%)‡ 0 4 (0.74%) 3 (0.10%)
 None of the above 4353 (49%) 3004 (48%) 2731 (50%) 175 (33%) 1425 (47%)
 Prior VTE 1352 (15%) 906 (14%) 821 (15%) 58 (11%) 419 (14%)
Underlying diseases
 Chronic heart failure 254 (2.9%) 775 (12%)‡ 720 (13%) 56 (10%) 469 (15%)
 Chronic lung disease 801 (9.1%) 1015 (16%)‡ 904 (16%) 62 (12%) 495 (16%)
 Recent major bleeding 170 (1.9%) 168 (2.7%)† 132 (2.4%) 15 (2.8%) 82 (2.7%)
Blood tests
 Anemia 2492 (28%) 2514 (40%)‡ 2116 (38%) 275 (51%) 1430 (47%)
 Platelet count <150 000/μL 1083 (12%) 1036 (17%)‡ 884 (16%) 70 (13%) 537 (18%)
 Platelet count >450 000/μL 249 (2.8%) 185 (3.0%) 151 (2.7%) 35 (6.5%) 95 (3.1%)
 CrCl levels (mL/min ± SD) 108 ± 50 54 ± 24‡ 55 ± 23 54 ± 38 36 ± 10
Initial VTE presentation
 Pulmonary embolism 4698 (53%) 3751 (60%)‡ 3364 (61%) 280 (52%) 1853 (61%)
CrCl, creatinine clearance; SD, standard deviation; VTE, venous thromboembolism.
Comparisons between fragile and non- fragile patients: *P < .05; †P < .01; ‡P < .001. Anemia was considered in men with haemoglobin levels <13 g/dL or 
women with levels <12 g/dL.
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variables were compared using the chi- square test (two- sided) and 
Fisher′s exact test (two- sided). Continuous variables were compared 
using Student’s t test. Odds ratios (OR) with 95% confidence intervals 
(CI), as well as P-values (Mann- Whitney test or t test for continuous 
variables and Cochran- Mantel- Haenszel tests for categorical vari-
ables) were presented for each variable analyzed. All outcomes were 
analyzed in the overall follow- up period (0- 90 days). Univariate analy-
sis was conducted yielding odds ratios with 95% CI, as well as P- values 
(Cochran- Mantel- Haenszel tests) for each outcome. Kaplan- Meier 
survival analysis was conducted to investigate the risk of outcomes in 
both subgroups for the overall period (0- 90 days).
Cox proportional hazard models were used to compare the rates of 
VTE recurrences and major bleeding in the two subgroups during the 
90- day follow- up period. Covariates included in the adjusted model 
were those for which a statistically significant difference (a threshold 
P- value of .1 was set to assess significance of differences) was found 
between the two subgroups, and a backward selection was used for 
the covariate selection in the multivariate model. For both Kaplan- 
Meier survival analyses and Cox regression analyses, if a patient 
did not have a study outcome of interest before the cut- off time of 
90 days or if he died, then the time- to- event was censored. Statistical 
analyses were conducted with SPSS for Windows Release 20.0 (SPSS, 
Inc., Chicago, Illinois).
3  | RESULTS
From January 2013 to October 2016, 15 079 patients with acute VTE 
were recruited in RIETE. Of these, 6260 (42%) were fragile: 5514 
(37%) were aged ≥75 years, 537 (3.6%) weighed ≤50 kg, and 3059 
(20%) had CrCl levels ≤50 mL/min. Fragile patients were less likely to 
be men (38% vs 57%) and more likely to have had recent immobility, 
cancer, chronic heart or lung disease, recent major bleeding, anemia, 
or abnormal platelet count than the non- fragile, but were less likely 
to have had recent surgery or estrogen use (Table 1). Fragile patients 
more likely presented initially with PE (with or without concomitant 
DVT) as compared with DVT alone (60% vs 53%).
Fragile patients more often received initial therapy with LMWH 
(88% vs 83%) or UFH (5.0% vs 4.3%), but less often fondaparinux 
(2.2% vs 3.6%) or rivaroxaban (2.4% vs 6.1%), as shown in Table 2. For 
long- term therapy, fragile patients more often received VKA (54% vs 
50%) and less often rivaroxaban (8.4% vs 17%) than the non- fragile. 
The proportion of patients receiving apixaban or dabigatran was small 
and similar in both subgroups. Moreover, fragile patients on long- term 
LMWH therapy received lower mean daily doses per body weight 
than the non- fragile. Mean duration of therapy was slightly shorter 
in fragile than in non- fragile patients (207 ± 190 vs 214 ± 179 days, 
respectively; P = .026).
During the first 3 months of anticoagulant therapy, fragile patients 
had a lower risk of VTE recurrences (0.78% vs 1.4%; OR: 0.56; 95% CI: 
0.40- 0.78) and a higher risk of major bleeding (2.6% vs 1.4%; OR: 1.86; 
95% CI: 1.47- 2.36) than the non- fragile (Table 3). The risk of DVT 
recurrences was particularly lower (0.37% vs 0.90%; OR: 0.41; 95% 
CI: 0.26- 0.65) while the risk of PE recurrences was non- significantly 
lower (0.43% vs 0.53%; OR: 0.81; 95% CI: 0.50- 1.30). Fragile patients 
also had a higher risk of all- cause death (9.2% vs 3.5%; OR: 2.82; 95% 
CI: 2.44- 3.25), fatal PE (0.85% vs 0.32%; OR: 2.68; 95% CI: 1.69- 4.24), 
and fatal bleeding (0.35% vs 0.19%; OR: 1.83; 95% CI: 0.97- 3.44) 
compared with non- fragile. In fragile patients, the risk of VTE recur-
rences was one- third the rate of major bleeding (49 vs 162 events, 
respectively) from the beginning of therapy (Figure 1). In non- fragile 
patients, both risks were similar (123 vs 124 events, respectively).
TABLE  2 Treatment strategies in fragile and non- fragile patients with acute venous thromboembolism
Non- fragile Fragile Age ≥75 y Weight ≤ 50 kg CrCl ≤ 50 mL/min
Patients, N 8819 6260 5514 537 3059
Initial therapy
 LMWH 7288 (83%) 5493 (88%)‡ 4879 (88%) 472 (88%) 2660 (87%)
 LMWH doses (IU/kg/d) 173 ± 43 172 ± 45 171 ± 44 187 ± 55 169 ± 47
 Unfractionated heparin 382 (4.3%) 316 (5.0%)* 244 (4.4%) 26 (4.8%) 215 (7.0%)
 Fondaparinux 317 (3.6%) 136 (2.2%)‡ 124 (2.2%) 13 (2.4%) 56 (1.8%)
 Rivaroxaban 534 (6.1%) 151 (2.4%)‡ 134 (2.4%) 14 (2.6%) 44 (1.4%)
 Apixaban 27 (0.31%) 17 (0.27%) 16 (0.29%) 1 (0.19%) 11 (0.36%)
Long- term therapy
 LMWH 2551 (29%) 1879 (30%) 1583 (29%) 242 (45%) 965 (32%)
 LMWH doses (IU/kg/d) 153 ± 44 146 ± 45‡ 145 ± 43 159 ± 48 144 ± 46
 Vitamin K antagonists 4415 (50%) 3401 (54%)‡ 3069 (56%) 192 (36%) 1643 (54%)
 Rivaroxaban 1452 (17%) 505 (8.4%)‡ 456 (8.6%) 42 (8.4%) 172 (6.0%)
 Apixaban 130 (1.5%) 93 (1.6%) 87 (1.6%) 7 (1.4%) 47 (1.6%)
 Dabigatran 28 (0.32%) 21 (0.35%) 21 (0.40%) 2 (0.40%) 6 (0.21%)
CrCl, creatinine clearance; IU, international units; LMWH, low- molecular- weight heparin.
Comparisons between fragile and non- fragile patients: *P < .05; †P < .01; ‡P < .001.
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When separately analyzing outcomes, the risk of major bleeding 
in patients weighing <50 kg was similar to the risk in non- fragile, in 
patients aged ≥75 years it was slightly (but significantly) higher, and 
in those with CrCl levels <50 mL/min it was over 3- fold higher than in 
non- fragile (Table 4).
4  | DISCUSSION
The term “fragile” has been recently incorporated into the literature 
to include VTE patients who are elderly, renally impaired, or with low 
body weight.3 This term should not be confused with “frail,” which 
usually refers to elderly people with reduced physiologic reserve asso-
ciated with increased susceptibility to disability.15–19 Our findings, 
obtained from a large series of consecutive patients with VTE, reveal 
that in real life 42% of patients were fragile, and that during the first 
3 months of anticoagulant therapy they had half the risk of VTE recur-
rences and a higher risk of major bleeding than the non- fragile. Among 
fragile patients, the risk of VTE recurrences was much lower than the 
risk of major bleeding (49 vs 162 events). Among non- fragile patients, 
the risk of VTE recurrences and major bleeding were the same (123 
vs 124 events, respectively). Thus, there are reasons to suggest that 
when choosing an anticoagulant therapy for fragile patients with VTE, 
safety is an important issue.
Recent randomized trials on patients with VTE provided indirect 
evidence on a number of advantages in fragile patients receiving 
DOACs.5,7,20 In the EINSTEIN- DVT and PE trials, the risk of major 
bleeding was much lower in fragile patients on rivaroxaban than in 
those on standard therapy (HR: 0.27; 95% CI: 0.13- 0.54).7 This dif-
ference was not seen in non- fragile patients. In the HOKUSAI trial a 
Fragile Non- fragile Crude OR (95% CI)
Adjusted OR  
(95% CI)
Patients, N 6260 8819
Events
 Recurrent VTE 49 (0.78%) 123 (1.4%) 0.56 (0.40- 0.78) 0.52 (0.37- 0.74)
 Recurrent PE 27 (0.43%) 47 (0.53%) 0.81 (0.50- 1.30) —
 Recurrent DVT 23 (0.37%) 79 (0.90%) 0.41 (0.26- 0.65) 0.41 (0.25- 0.67)
 Major bleeding 162 (2.6%) 124 (1.4%) 1.86 (1.47- 2.36) 1.41 (1.10- 1.80)
Sites of major bleeding
 Gastrointestinal 54 (0.86%) 31 (0.35%) 2.47 (1.58- 3.84) 1.84 (1.16- 2.92)
 Cerebral 20 (0.32%) 21 (0.24%) 1.34 (0.73- 2.48) —
 Haematoma 32 (0.51%) 6 (0.07%) 7.55 (3.15- 18.1) 5.05 (2.05- 12.4)
 Retroperitoneal 16 (0.26%) 11 (0.12%) 2.05 (0.95- 4.42) —
Death 574 (9.2%) 305 (3.5%) 2.82 (2.44- 3.25) 2.02 (1.75- 2.33)
Causes of death
 Pulmonary 
embolism
53 (0.85%) 28 (0.32%) 2.68 (1.69- 4.24) 1.77 (1.10- 2.85)
 Initial PE 49 (0.78%) 23 (0.26%) 3.02 (1.84- 4.96) 1.91 (1.14- 3.20)
 Recurrent PE 4 (0.06%) 5 (0.06%) 1.13 (0.30- 4.20) —
 Bleeding 22 (0.35%) 17 (0.19%) 1.83 (0.97- 3.44) —
 Cerebral 8 (0.13%) 6 (0.07%) 1.88 (0.65- 5.42) —
 Gastrointestinal 4 (0.06%) 3 (0.03%) 1.88 (0.42- 8.40) —
 Retroperitoneal 5 (0.08%) 1 (0.01%) 7.05 (0.82- 60.3) —
 Respiratory 
insufficiency
44 (0.70%) 24 (0.27%) 2.59 (1.58- 4.27) —
 Sudden, 
unexpected
16 (0.26%) 12 (0.14%) 1.88 (0.89- 3.98) —
CI, confidence intervals; DVT, deep vein thrombosis; OR, odds ratio; PE, pulmonary embolism; VTE, 
venous thromboembolism.
Variables included in the multivariable analysis for VTE recurrence: fragile, active cancer, prior VTE, chronic 
heart failure, abnormal platelet count, and initial VTE presentation (DVT or PE).
Variables included in the multivariable analysis for major bleeding: fragile, gender, active cancer, chronic 
lung disease, recent major bleeding, anaemia, abnormal platelet count, and initial VTE presentation 
(DVT or PE).
Variables included in the multivariable analysis for death: fragile, gender, active cancer, recent surgery, 
recent immobilization, prior VTE, chronic lung disease, chronic heart failure, recent major bleeding, 
anaemia, abnormal platelet count, and initial VTE presentation (DVT or PE).
TABLE  3 Clinical outcomes during the 
first 3 months of anticoagulant therapy in 
fragile vs non- fragile patients with VTE
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higher efficacy (defined as symptomatic recurrent venous thrombo-
embolism) was found using edoxaban than with warfarin in fragile 
patients (2.5% vs 4.8%; P = .04), without any safety concern (11.0% 
vs 13.7%; P = .87).5 Unexpectedly, however, in our cohort rivaroxaban 
was less likely to be prescribed in fragile than in non- fragile patients, 
both initially (2.4% vs 6.1%, respectively) and for long- term therapy 
(8.4% vs 17%).
Our data confirm that the use of anticoagulant therapy carries 
a higher risk to bleed than to recur in the elderly and in the renally 
impaired, as previously reported.14,21–25 During initial therapy with 
F I G U R E  1 Cumulative incidence of venous thromboembolism (VTE) recurrence and major bleeding during the first 3 months of 
anticoagulant therapy in fragile vs non- fragile patients
Days 1 10 30 60 90
Fragile 
VTE recurrences 5 (0.08%) 10 (0.16%) 26 (0.43%) 41 (0.7%) 49 (0.87%)
Major bleeding 18 (0.29%) 74 (1.2%) 124 (2.05%) 152 (2.54%) 162 (2.72%)
Non-fragile
VTE recurrences 7 (0.08%) 31 (0.35%) 60 (0.69%) 97 (1.13%) 123 (1.45%)
Major bleeding 10 (0.11%) 51 (0.58%) 82 (0.94%) 105 (1.21%) 124 (1.46%)
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Fragile, VTE recurrences
Non fragile, VTE recurrences
Fragile, major bleeding
Non fragile, major bleeding
N
VTE recurrences Major bleeding
N (%) OR (95% CI) N (%) OR (95% CI)
Non- fragile 8819 123 (1.4%) Ref. 124 (1.4%) Ref.
Age ≥75 years 
only
2967 22 (0.7%) 0.5 (0.3- 0.8) 62 (2.1%) 1.5 (1.1- 2.0)
CrCl ≤50 mL/
min only
521 6 (1.2%) 0.8 (0.3- 1.8) 23 (4.4%) 3.2 (2.0- 5.0)
Body weight 
≤50 kg only
183 3 (1.6%) 1.2 (0.3- 3.3) 2 (1.1%) 0.8 (0.1- 2.6)
Age ≥75 years 
and CrCl 
≤50 mL/min
2235 16 (0.7%) 0.5 (0.3- 0.8) 60 (2.7%) 1.9 (1.4- 2.6)
Age ≥75 years 
and body 
weight ≤50 kg
51 0 — 1 (2.0%) 1.4 (0.1- 7.3)
CrCl ≤50 mL/
min and weight 
≤50 kg
42 1 (2.4%) 1.7 (0.1- 9.0) 2 (4.8%) 3.5 (0.6- 12.4)
All 3 conditions 261 1 (0.4%) 0.3 (0.01- 1.4) 12 (4.6%) 3.4 (1.8- 6.0)
CI, confidence intervals; CrCl, creatinine clearance; OR, odds ratio; Ref., reference; VTE, venous 
thromboembolism.
TABLE  4 Rates of VTE recurrences and 
major bleeding, according to the presence 
of age ≥75 years, CrCl ≤50 mL/min and/or 
body weight ≤50 kg
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LMWH, fragile patients weighing ≤50 kg received slightly higher 
(non- significantly) mean daily doses per body weight of LMWH com-
pared with non- fragile patients. This might explain, at least in part, the 
higher risk of major bleeding in fragile patients. Moreover, since frag-
ile patients had more underlying diseases, they probably used more 
drugs than the non- fragile patients. Thus, the increased risks of major 
bleeding during anticoagulation in fragile patients could be explained, 
at least in part, by these other drugs that might have potentiated the 
effect of the anticoagulant therapy. The similar risk for bleeding than 
for VTE recurrences in VTE patients weighing ≤50 kg has not been 
consistently reported.26–28 These findings suggest the potential ben-
efit of tailored therapy for VTE according to clinical characteristics of 
the patients and warrant external validation.
The present study has a number of potential limitations. First, 
since RIETE is an observational registry (and not a randomized trial) 
our data are hypothesis- generating. They might be a useful basis for 
future controlled clinical trials comparing different therapeutic strat-
egies, but we should be extremely cautious in suggesting changes 
in treatment strategies just because of uncontrolled registry data. 
Second, patients were not treated with a standardized anticoagulant 
regimen; treatment varied with local practice, and is likely to have 
been influenced by a physician’s assessment of a patient’s risk of 
bleeding. Finally, patients in the RIETE database resided in several 
different countries. The variability of practices in different countries 
could potentially affect the study outcomes. Furthermore, a variety of 
practitioners entered data into the registry, which may lend itself to 
potential inaccuracies in the data being reported. The main strengths 
of our observation are the high number of included patients, the 
strict diagnostic criteria and the reporting of objectively established 
outcomes (major bleeding and recurrent VTE). Additionally, the 
population- based sample we used describes the effects of anticoagu-
lant therapy in “real- world” clinical care, as opposed to in a protocol- 
driven randomized trial, and enhances the generalizability of our 
findings.
In summary, in real life 42% of VTE patients were fragile, and 
these patients had fewer VTE recurrences and more major bleeding 
events during the course of anticoagulant therapy than the non- 
fragile. Randomized trials are warranted to confirm whether the use of 
DOACs could be safer than standard anticoagulant therapy in fragile 
patients with VTE.
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